ZIM Laboratories Limited (NSE:ZIMLAB)

Market Cap	5.36B +27.0%
Revenue (ttm)	3.74B -1.2%
Net Income	58.38M -52.0%
EPS	1.19 -52.3%
Shares Out	n/a
PE Ratio	91.76
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	69,455
Average Volume	132,776
Open	100.11
Previous Close	100.11
Day's Range	99.50 - 103.00
52-Week Range	59.31 - 127.00
Beta	0.79
RSI	63.02
Earnings Date	May 19, 2026

About ZIM Laboratories

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 577
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ZIMLAB

Financial Performance

In fiscal year 2026, ZIM Laboratories's revenue was 3.74 billion, a decrease of -1.25% compared to the previous year's 3.79 billion. Earnings were 58.38 million, a decrease of -52.01%.